Latest News

LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer


KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–LYNPARZA PAOLA-1 Trial Significantly Increased PFS as 1st-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer

Source link




Related posts

Higher antibiotic exposure linked to increased risk of Parkinson's disease

Newsemia

10 Supplements Everyone Should Take

Newsemia

Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy